Paradigm Announces Major Price Reduction in Flagship Paradigm Cancer Diagnostic (PCDx)

On July 24, 2017, Paradigm Diagnostics announced a major price reduction of PCDx.  “The efficiency of our proprietary process and transition to an optimized platform enables us to share the savings with our patients, customers, research partners, and distributors without impacting our industry leading accuracy, speed, and comprehensiveness,” said David Mallery, CEO.

Continue reading